ASCO GI 2023 | How will fruquintinib fit in the colorectal cancer treatment landscape?

Arvind Dasari, MD, MS, The University of Texas MD Anderson Cancer Center, Houston, TX, talks on the future role of fruquintinib in the treatment landscape of colorectal cancer. The FRESCO (NCT02314819) and FRESCO-2 (NCT04322539) trials have provided data showing the efficacy of fruquintinib in third line settings and beyond. The drug will consequently complement trifluridine and tipiracil in combination with bevacizumab, which was assessed in the SUNLIGHT trial (NCT04737187). This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

View our new feature exploring genomic biomarkers in metastatic colorectal cancer here: https://bit.ly/3DcSevZ